668 related articles for article (PubMed ID: 23658368)
1. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes.
Gehrmann U; Hiltbrunner S; Georgoudaki AM; Karlsson MC; Näslund TI; Gabrielsson S
Cancer Res; 2013 Jul; 73(13):3865-76. PubMed ID: 23658368
[TBL] [Abstract][Full Text] [Related]
2. Attenuation of invariant natural killer T-cell anergy induction through intradermal delivery of alpha-galactosylceramide.
Bontkes HJ; Moreno M; Hangalapura B; Lindenberg JJ; de Groot J; Lougheed S; van der Vliet HJ; van den Eertwegh AJ; de Gruijl TD; von Blomberg BM; Scheper RJ
Clin Immunol; 2010 Sep; 136(3):364-74. PubMed ID: 20570567
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells.
Matsuyoshi H; Hirata S; Yoshitake Y; Motomura Y; Fukuma D; Kurisaki A; Nakatsura T; Nishimura Y; Senju S
Cancer Sci; 2005 Dec; 96(12):889-96. PubMed ID: 16367909
[TBL] [Abstract][Full Text] [Related]
4. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.
Choi DH; Kim KS; Yang SH; Chung DH; Song B; Sprent J; Cho JH; Sung YC
Cancer Res; 2011 Dec; 71(24):7442-51. PubMed ID: 22028323
[TBL] [Abstract][Full Text] [Related]
6. Invariant NKT cell anergy is induced by a strong TCR-mediated signal plus co-stimulation.
Iyoda T; Ushida M; Kimura Y; Minamino K; Hayuka A; Yokohata S; Ehara H; Inaba K
Int Immunol; 2010 Nov; 22(11):905-13. PubMed ID: 21118907
[TBL] [Abstract][Full Text] [Related]
7. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity.
Hokey DA; Larregina AT; Erdos G; Watkins SC; Falo LD
Cancer Res; 2005 Nov; 65(21):10059-67. PubMed ID: 16267032
[TBL] [Abstract][Full Text] [Related]
8. NKT Cell-Driven Enhancement of Antitumor Immunity Induced by Clec9a-Targeted Tailorable Nanoemulsion.
Lam PY; Kobayashi T; Soon M; Zeng B; Dolcetti R; Leggatt G; Thomas R; Mattarollo SR
Cancer Immunol Res; 2019 Jun; 7(6):952-962. PubMed ID: 31053598
[TBL] [Abstract][Full Text] [Related]
9. Tumor cells loaded with α-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma.
Hong S; Lee H; Jung K; Lee SM; Lee SJ; Jun HJ; Kim Y; Song H; Bogen B; Choi I
Immunol Lett; 2013; 156(1-2):132-9. PubMed ID: 24148970
[TBL] [Abstract][Full Text] [Related]
10. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
[TBL] [Abstract][Full Text] [Related]
11. Sulfatide inhibits α-galactosylceramide presentation by dendritic cells.
Kanamori M; Tasumi Y; Iyoda T; Ushida M; Inaba K
Int Immunol; 2012 Feb; 24(2):129-36. PubMed ID: 22247226
[TBL] [Abstract][Full Text] [Related]
12. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
13. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells recruit T cell exosomes via exosomal LFA-1 leading to inhibition of CD8+ CTL responses through downregulation of peptide/MHC class I and Fas ligand-mediated cytotoxicity.
Xie Y; Zhang H; Li W; Deng Y; Munegowda MA; Chibbar R; Qureshi M; Xiang J
J Immunol; 2010 Nov; 185(9):5268-78. PubMed ID: 20881190
[TBL] [Abstract][Full Text] [Related]
15. Role of marginal zone B lymphocytes in invariant NKT cell activation.
Bialecki E; Paget C; Fontaine J; Capron M; Trottein F; Faveeuw C
J Immunol; 2009 May; 182(10):6105-13. PubMed ID: 19414762
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with antigen-transfected, NKT cell ligand-loaded, human cells elicits robust in situ immune responses by dendritic cells.
Shimizu K; Mizuno T; Shinga J; Asakura M; Kakimi K; Ishii Y; Masuda K; Maeda T; Sugahara H; Sato Y; Matsushita H; Nishida K; Hanada K; Dorrie J; Schaft N; Bickham K; Koike H; Ando T; Nagai R; Fujii S
Cancer Res; 2013 Jan; 73(1):62-73. PubMed ID: 23108144
[TBL] [Abstract][Full Text] [Related]
17. The nanoparticulation by octaarginine-modified liposome improves α-galactosylceramide-mediated antitumor therapy via systemic administration.
Nakamura T; Yamazaki D; Yamauchi J; Harashima H
J Control Release; 2013 Oct; 171(2):216-24. PubMed ID: 23860186
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes.
Hao S; Bai O; Yuan J; Qureshi M; Xiang J
Cell Mol Immunol; 2006 Jun; 3(3):205-11. PubMed ID: 16893501
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity.
Näslund TI; Gehrmann U; Qazi KR; Karlsson MC; Gabrielsson S
J Immunol; 2013 Mar; 190(6):2712-9. PubMed ID: 23418627
[TBL] [Abstract][Full Text] [Related]
20. Asthma is induced by intranasal coadministration of allergen and natural killer T-cell ligand in a mouse model.
Kim JO; Kim DH; Chang WS; Hong C; Park SH; Kim S; Kang CY
J Allergy Clin Immunol; 2004 Dec; 114(6):1332-8. PubMed ID: 15577831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
